Pancreas–Microbiota Cross Talk in Health and Disease

Literature Cited

1. 1.

   Adolph TE, Grander C, Moschen AR, Tilg H 2018. Liver–microbiome axis in health and disease. Trends Immunol 39:712–23
   [Google Scholar]
2. 2.

   Adolph TE, Mayr L, Grabherr F, Tilg H 2018. Paneth cells and their antimicrobials in intestinal immunity. Curr. Pharm. Des. 24:1121–29
   [Google Scholar]
3. 3.

   Ahuja M, Schwartz DM, Tandon M, Son A, Zeng M et al. 2017. Orai1-mediated antimicrobial secretion from pancreatic acini shapes the gut microbiome and regulates gut innate immunity. Cell Metab 25:635–46
   [Google Scholar]
4. 4.

   Alkanani AK, Hara N, Gottlieb PA, Ir D, Robertson CE et al. 2015. Alterations in intestinal microbiota correlate with susceptibility to type 1 diabetes. Diabetes 64:3510–20
   [Google Scholar]
5. 5.

   Amyot J, Semache M, Ferdaoussi M, Fontes G, Poitout V 2012. Lipopolysaccharides impair insulin gene expression in isolated islets of Langerhans via Toll-Like Receptor-4 and NF-κB signalling. PLOS ONE 7:e36200
   [Google Scholar]
6. 6.

   Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T et al. 2011. Enterotypes of the human gut microbiome. Nature 473:174–80
   [Google Scholar]
7. 7.

   Atkinson MA, Eisenbarth GS, Michels AW 2014. Type 1 diabetes. Lancet 383:69–82
   [Google Scholar]
8. 8.

   Backe MB, Moen IW, Ellervik C, Hansen JB, Mandrup-Poulsen T 2016. Iron regulation of pancreatic β-cell functions and oxidative stress. Annu. Rev. Nutr. 36:241–73
   [Google Scholar]
9. 9.

   Bäckhed F, Ding H, Wang T, Hooper LV, Koh GY et al. 2004. The gut microbiota as an environmental factor that regulates fat storage. PNAS 101:15718–23
   [Google Scholar]
10. 10.

    Belkaid Y, Hand TW. 2014. Role of the microbiota in immunity and inflammation. Cell 157:121–41
    [Google Scholar]
11. 11.

    Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB et al. 2012. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491:399–405
    [Google Scholar]
12. 12.

    Bouziat R, Hinterleitner R, Brown JJ, Stencel-Baerenwald JE, Ikizler M et al. 2017. Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science 356:44–50
    [Google Scholar]
13. 13.

    Burrows MP, Volchkov P, Kobayashi KS, Chervonsky AV 2015. Microbiota regulates type 1 diabetes through Toll-like receptors. PNAS 112:9973–77
    [Google Scholar]
14. 14.

    Cani PD. 2018. Human gut microbiome: hopes, threats and promises. Gut 67:1716–25
    [Google Scholar]
15. 15.

    Cani PD, Jordan BF. 2018. Gut microbiota–mediated inflammation in obesity: a link with gastrointestinal cancer. Nat. Rev. Gastroenterol. Hepatol. 15:671–82
    [Google Scholar]
16. 16.

    Caporaso JG, Lauber CL, Costello EK, Berg-Lyons D, Gonzalez A et al. 2011. Moving pictures of the human microbiome. Genome Biol 12:R50
    [Google Scholar]
17. 17.

    Charbonneau MR, Blanton LV, DiGiulio DB, Relman DA, Lebrilla CB et al. 2016. A microbial perspective of human developmental biology. Nature 535:48–55
    [Google Scholar]
18. 18.

    Chatterjee S, Khunti K, Davies MJ 2017. Type 2 diabetes. Lancet 389:2239–51
    [Google Scholar]
19. 19.

    Chen J, Domingue JC, Sears CL 2017. Microbiota dysbiosis in select human cancers: evidence of association and causality. Semin. Immunol. 32:25–34
    [Google Scholar]
20. 20.

    Chromek M, Slamova Z, Bergman P, Kovacs L, Podracka L et al. 2006. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. 12:636–41
    [Google Scholar]
21. 21.

    Ciocan D, Rebours V, Voican CS, Wrzosek L, Puchois V et al. 2018. Characterization of intestinal microbiota in alcoholic patients with and without alcoholic hepatitis or chronic alcoholic pancreatitis. Sci. Rep. 8:4822
    [Google Scholar]
22. 22.

    Costa FR, Francozo MC, de Oliveira GG, Ignacio A, Castoldi A et al. 2016. Gut microbiota translocation to the pancreatic lymph nodes triggers NOD2 activation and contributes to T1D onset. J. Exp. Med. 213:1223–39
    [Google Scholar]
23. 23.

    Costea PI, Hildebrand F, Manimozhiyan A, Bäckhed F, Blaser MJ et al. 2018. Enterotypes in the landscape of gut microbial community composition. Nat. Microbiol. 3:8–16
    [Google Scholar]
24. 24.

    Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N et al. 2013. Dietary intervention impact on gut microbial gene richness. Nature 500:585–88
    [Google Scholar]
25. 25.

    Danai LV, Babic A, Rosenthal MH, Dennstedt EA, Muir A et al. 2018. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558:600–4
    [Google Scholar]
26. 26.

    Dao MC, Everard A, Aron-Wisnewsky J, Sokolovska N, Prifti E et al. 2016. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65:426–36
    [Google Scholar]
27. 27.

    David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE et al. 2014. Diet rapidly and reproducibly alters the human gut microbiome. Nature 505:559–63
    [Google Scholar]
28. 28.

    Deng YY, Shamoon M, He Y, Bhatia M, Sun J 2016. Cathelicidin-related antimicrobial peptide modulates the severity of acute pancreatitis in mice. Mol. Med. Rep. 13:3881–85
    [Google Scholar]
29. 29.

    Dickson I. 2018. Microbiome promotes pancreatic cancer. Nat. Rev. Gastroenterol. Hepatol. 15:328
    [Google Scholar]
30. 30.

    Dumas ME, Rothwell AR, Hoyles L, Aranias T, Chilloux J et al. 2017. Microbial–host co-metabolites are prodromal markers predicting phenotypic heterogeneity in behavior, obesity, and impaired glucose tolerance. Cell Rep 20:136–48
    [Google Scholar]
31. 31.

    Durack J, Lynch SV. 2018. The gut microbiome: relationships with disease and opportunities for therapy. J. Exp. Med. 216:20–40
    [Google Scholar]
32. 32.

    Endesfelder D, Engel M, Davis-Richardson AG, Ardissone AN, Achenbach P et al. 2016. Towards a functional hypothesis relating anti-islet cell autoimmunity to the dietary impact on microbial communities and butyrate production. Microbiome 4:17
    [Google Scholar]
33. 33.

    Endesfelder D, zu Castell W, Ardissone A, Davis-Richardson AG, Achenbach P et al. 2014. Compromised gut microbiota networks in children with anti-islet cell autoimmunity. Diabetes 63:2006–14
    [Google Scholar]
34. 34.

    Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C et al. 2013. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. PNAS 110:9066–71
    [Google Scholar]
35. 35.

    Fan X, Alekseyenko AV, Wu J, Peters BA, Jacobs EJ et al. 2018. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case–control study. Gut 67:120–27
    [Google Scholar]
36. 36.

    Fan X, Peters BA, Jacobs EJ, Gapstur SM, Purdue MP et al. 2018. Drinking alcohol is associated with variation in the human oral microbiome in a large study of American adults. Microbiome 6:59
    [Google Scholar]
37. 37.

    Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D et al. 2012. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61:582–88
    [Google Scholar]
38. 38.

    Forbes JD, Van Domselaar G, Bernstein CN 2016. The gut microbiota in immune-mediated inflammatory diseases. Front. Microbiol. 7:1081
    [Google Scholar]
39. 39.

    Forsmark CE, Vege SS, Wilcox CM 2016. Acute pancreatitis. N. Engl. J. Med. 375:1972–81
    [Google Scholar]
40. 40.

    Gallo RL, Kim KJ, Bernfield M, Kozak CA, Zanetti M et al. 1997. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J. Biol. Chem. 272:13088–93
    [Google Scholar]
41. 41.

    Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ et al. 2006. Metagenomic analysis of the human distal gut microbiome. Science 312:1355–59
    [Google Scholar]
42. 42.

    Gillen S, Schuster T, Meyer zum Büschenfelde C, Friess H, Kleeff J 2010. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLOS Med 7:e1000267
    [Google Scholar]
43. 43.

    Gittes GK. 2009. Developmental biology of the pancreas: a comprehensive review. Dev. Biol. 326:4–35
    [Google Scholar]
44. 44.

    Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC et al. 2018. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359:97–103
    [Google Scholar]
45. 45.

    Groele L, Szajewska H, Szypowska A 2017. Effects of Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12 on β-cell function in children with newly diagnosed type 1 diabetes: protocol of a randomised controlled trial. BMJ Open 7:e017178
    [Google Scholar]
46. 46.

    Gu G, Dubauskaite J, Melton DA 2002. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development 129:2447–57
    [Google Scholar]
47. 47.

    Hamada S, Masamune A, Nabeshima T, Shimosegawa T 2018. Differences in gut microbiota profiles between autoimmune pancreatitis and chronic pancreatitis. Tohoku J. Exp. Med. 244:113–17
    [Google Scholar]
48. 48.

    Hanninen A, Toivonen R, Poysti S, Belzer C, Plovier H et al. 2018. Akkermansia muciniphila induces gut microbiota remodelling and controls islet autoimmunity in NOD mice. Gut 67:1445–53
    [Google Scholar]
49. 49.

    Hooper LV, Littman DR, Macpherson AJ 2012. Interactions between the microbiota and the immune system. Science 336:1268–73
    [Google Scholar]
50. 50.

    Hooper LV, Macpherson AJ. 2010. Immune adaptations that maintain homeostasis with the intestinal microbiota. Nat. Rev. Immunol. 10:159–69
    [Google Scholar]
51. 51.

    Huang C, Chen J, Wang J, Zhou H, Lu Y et al. 2017. Dysbiosis of intestinal microbiota and decreased antimicrobial peptide level in Paneth cells during hypertriglyceridemia-related acute necrotizing pancreatitis in rats. Front. Microbiol. 8:776
    [Google Scholar]
52. 52.

    Ianiro G, Tilg H, Gasbarrini A 2016. Antibiotics as deep modulators of gut microbiota: between good and evil. Gut 65:1906–15
    [Google Scholar]
53. 53.

    Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z et al. 2016. Proton pump inhibitors affect the gut microbiome. Gut 65:740–48
    [Google Scholar]
54. 54.

    Issa Y, Bruno MJ, Bakker OJ, Besselink MG, Schepers NJ et al. 2014. Treatment options for chronic pancreatitis. Nat. Rev. Gastroenterol. Hepatol. 11:556–64
    [Google Scholar]
55. 55.

    Jandhyala SM, Madhulika A, Deepika G, Rao GV, Reddy DN et al. 2017. Altered intestinal microbiota in patients with chronic pancreatitis: implications in diabetes and metabolic abnormalities. Sci. Rep. 7:43640
    [Google Scholar]
56. 56.

    Jia L, Shan K, Pan LL, Feng N, Lv Z et al. 2017. Clostridium butyricum CGMCC0313.1 protects against autoimmune diabetes by modulating intestinal immune homeostasis and inducing pancreatic regulatory T cells. Front. Immunol. 8:1345
    [Google Scholar]
57. 57.

    Jia W, Xie G, Jia W 2018. Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat. Rev. Gastroenterol. Hepatol. 15:111–28
    [Google Scholar]
58. 58.

    Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ et al. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–6
    [Google Scholar]
59. 59.

    Kahn SE, Cooper ME, Del Prato S 2014. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383:1068–83
    [Google Scholar]
60. 60.

    Kahn SE, Hull RL, Utzschneider KM 2006. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840–46
    [Google Scholar]
61. 61.

    Kamisawa T, Wood LD, Itoi T, Takaori K 2016. Pancreatic cancer. Lancet 388:73–85
    [Google Scholar]
62. 62.

    Kamisawa T, Zen Y, Pillai S, Stone JH 2015. IgG4-related disease. Lancet 385:1460–71
    [Google Scholar]
63. 63.

    Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J 2000. Incidence of childhood type 1 diabetes worldwide: Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 23:1516–26
    [Google Scholar]
64. 64.

    Keller J, Layer P. 2005. Human pancreatic exocrine response to nutrients in health and disease. Gut 54:Suppl. 61–28
    [Google Scholar]
65. 65.

    Kosciuczuk EM, Lisowski P, Jarczak J, Strzalkowska N, Jozwik A et al. 2012. Cathelicidins: family of antimicrobial peptides. A review. Mol. Biol. Rep. 39:10957–70
    [Google Scholar]
66. 66.

    Kountouras J, Zavos C, Gavalas E, Tzilves D 2007. Challenge in the pathogenesis of autoimmune pancreatitis: potential role of Helicobacter pylori infection via molecular mimicry. Gastroenterology 133:368–69
    [Google Scholar]
67. 67.

    Kriegel MA, Sefik E, Hill JA, Wu HJ, Benoist C, Mathis D 2011. Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. PNAS 108:11548–53
    [Google Scholar]
68. 68.

    Lankisch PG, Apte M, Banks PA 2015. Acute pancreatitis. Lancet 386:85–96
    [Google Scholar]
69. 69.

    Li Q, Wang C, Tang C, Zhao X, He Q, Li J 2018. Identification and characterization of blood and neutrophil-associated microbiomes in patients with severe acute pancreatitis using next-generation sequencing. Front. Cell. Infect. Microbiol. 8:5
    [Google Scholar]
70. 70.

    Li X, Watanabe K, Kimura I 2017. Gut microbiota dysbiosis drives and implies novel therapeutic strategies for diabetes mellitus and related metabolic diseases. Front. Immunol. 8:1882
    [Google Scholar]
71. 71.

    Liang D, Leung RK, Guan W, Au WW 2018. Involvement of gut microbiome in human health and disease: brief overview, knowledge gaps and research opportunities. Gut Pathog 10:3
    [Google Scholar]
72. 72.

    Lynch SV, Pedersen O. 2016. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375:2369–79
    [Google Scholar]
73. 73.

    Ma C, Han M, Heinrich B, Fu Q, Zhang Q et al. 2018. Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells. Science 360:eaan5931
    [Google Scholar]
74. 74.

    Majumder S, Chari ST. 2016. Chronic pancreatitis. Lancet 387:1957–66
    [Google Scholar]
75. 75.

    Manfredo Vieira S, Hiltensperger M, Kumar V, Zegarra-Ruiz D, Dehner C et al. 2018. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 359:1156–61
    [Google Scholar]
76. 76.

    Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM et al. 2016. The gut microbiota and host health: a new clinical frontier. Gut 65:330–39
    [Google Scholar]
77. 77.

    Marino E, Richards JL, McLeod KH, Stanley D, Yap YA et al. 2017. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes. Nat. Immunol. 18:552–62
    [Google Scholar]
78. 78.

    Markle JG, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM et al. 2013. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science 339:1084–88
    [Google Scholar]
79. 79.

    McCarl CA, Picard C, Khalil S, Kawasaki T, Rother J et al. 2009. ORAI1 deficiency and lack of store-operated Ca²⁺ entry cause immunodeficiency, myopathy, and ectodermal dysplasia. J. Allergy Clin. Immunol. 124:1311–18.e7
    [Google Scholar]
80. 80.

    Memba R, Duggan SN, Ni Chonchubhair HM, Griffin OM, Bashir Y et al. 2017. The potential role of gut microbiota in pancreatic disease: a systematic review. Pancreatology 17:867–74
    [Google Scholar]
81. 81.

    Metzger RN, Krug AB, Eisenacher K 2018. Enteric virome sensing—its role in intestinal homeostasis and immunity. Viruses 10:146
    [Google Scholar]
82. 82.

    Mitsuhashi K, Nosho K, Sukawa Y, Matsunaga Y, Ito M et al. 2015. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 6:7209–20
    [Google Scholar]
83. 83.

    Moschen AR, Wieser V, Tilg H 2012. Dietary factors: major regulators of the gut's microbiota. Gut Liver 6:411–16
    [Google Scholar]
84. 84.

    Mullaney JA, Stephens JE, Costello ME, Fong C, Geeling BE et al. 2018. Type 1 diabetes susceptibility alleles are associated with distinct alterations in the gut microbiota. Microbiome 6:35
    [Google Scholar]
85. 85.

    Niederreiter L, Adolph TE, Tilg H 2018. Food, microbiome and colorectal cancer. Dig. Liver Dis. 50:647–52
    [Google Scholar]
86. 86.

    Ochi A, Nguyen AH, Bedrosian AS, Mushlin HM, Zarbakhsh S et al. 2012. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J. Exp. Med. 209:1671–87
    [Google Scholar]
87. 87.

    Pagliari D, Saviano A, Newton EE, Serricchio ML, Dal Lago AA et al. 2018. Gut microbiota–immune system crosstalk and pancreatic disorders. Mediat. Inflamm. 2018:7946431
    [Google Scholar]
88. 88.

    Passero FC Jr, Saif MW. 2017. Second line treatment options for pancreatic cancer. Expert Opin. Pharmacother. 18:1607–17
    [Google Scholar]
89. 89.

    Perry RJ, Peng L, Barry NA, Cline GW, Zhang D et al. 2016. Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome. Nature 534:213–17
    [Google Scholar]
90. 90.

    Peschel A, Sahl HG. 2006. The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat. Rev. Microbiol. 4:529–36
    [Google Scholar]
91. 91.

    Plovier H, Everard A, Druart C, Depommier C, Van Hul M et al. 2017. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23:107–13
    [Google Scholar]
92. 92.

    Ponziani FR, Bhoori S, Castelli C, Putignani L, Rivoltini L et al. 2019. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in non-alcoholic fatty liver disease. Hepatology 69:107–20
    [Google Scholar]
93. 93.

    Pound LD, Patrick C, Eberhard CE, Mottawea W, Wang GS et al. 2015. Cathelicidin antimicrobial peptide: a novel regulator of islet function, islet regeneration, and selected gut bacteria. Diabetes 64:4135–47
    [Google Scholar]
94. 94.

    Pushalkar S, Hundeyin M, Daley D, Zambirinis CP, Kurz E et al. 2018. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov 8:403–16
    [Google Scholar]
95. 95.

    Qin J, Li Y, Cai Z, Li S, Zhu J et al. 2012. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490:55–60
    [Google Scholar]
96. 96.

    Ren Z, Jiang J, Xie H, Li A, Lu H et al. 2017. Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget 8:95176–91
    [Google Scholar]
97. 97.

    Roder PV, Wu B, Liu Y, Han W 2016. Pancreatic regulation of glucose homeostasis. Exp. Mol. Med. 48:e219
    [Google Scholar]
98. 98.

    Rogers MB, Aveson V, Firek B, Yeh A, Brooks B et al. 2017. Disturbances of the perioperative microbiome across multiple body sites in patients undergoing pancreaticoduodenectomy. Pancreas 46:260–67
    [Google Scholar]
99. 99.

    Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT et al. 2018. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91–97
    [Google Scholar]
100. 100.

     Rouxel O, Da Silva J, Beaudoin L, Nel I, Tard C et al. 2017. Cytotoxic and regulatory roles of mucosal-associated invariant T cells in type 1 diabetes. Nat. Immunol. 18:1321–31
     [Google Scholar]
101. 101.

     Sartor RB. 2008. Microbial influences in inflammatory bowel diseases. Gastroenterology 134:577–94
     [Google Scholar]
102. 102.

     Sears CL, Garrett WS. 2014. Microbes, microbiota, and colon cancer. Cell Host Microbe 15:317–28
     [Google Scholar]
103. 103.

     Seifert L, Werba G, Tiwari S, Giao Ly NN, Alothman S et al. 2016. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 532:245–49
     [Google Scholar]
104. 104.

     Sekirov I, Russell SL, Antunes LC, Finlay BB 2010. Gut microbiota in health and disease. Physiol. Rev. 90:859–904
     [Google Scholar]
105. 105.

     Sender R, Fuchs S, Milo R 2016. Revised estimates for the number of human and bacteria cells in the body. PLOS Biol 14:e1002533
     [Google Scholar]
106. 106.

     Sethi V, Kurtom S, Tarique M, Lavania S, Malchiodi Z et al. 2018. Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterology 155:33–37.e6
     [Google Scholar]
107. 107.

     Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R et al. 2006. International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med. 355:1318–30
     [Google Scholar]
108. 108.

     Shih HP, Wang A, Sander M 2013. Pancreas organogenesis: from lineage determination to morphogenesis. Annu. Rev. Cell Dev. Biol. 29:81–105
     [Google Scholar]
109. 109.

     Silverman M, Kua L, Tanca A, Pala M, Palomba A et al. 2017. Protective major histocompatibility complex allele prevents type 1 diabetes by shaping the intestinal microbiota early in ontogeny. PNAS 114:9671–76
     [Google Scholar]
110. 110.

     Simeone DM, Pandol SJ. 2013. The pancreas: biology, diseases, and therapy. Gastroenterology 144:1163–65
     [Google Scholar]
111. 111.

     Soares FS, Amaral FC, Silva NLC, Valente MR, Santos LKR et al. 2017. Antibiotic-induced pathobiont dissemination accelerates mortality in severe experimental pancreatitis. Front. Immunol. 8:1890
     [Google Scholar]
112. 112.

     Song M, Garrett WS, Chan AT 2015. Nutrients, foods, and colorectal cancer prevention. Gastroenterology 148:1244–60.e16
     [Google Scholar]
113. 113.

     Sonnenburg JL, Bäckhed F. 2016. Diet–microbiota interactions as moderators of human metabolism. Nature 535:56–64
     [Google Scholar]
114. 114.

     Stewart CJ, Ajami NJ, O'Brien JL, Hutchinson DS, Smith DP et al. 2018. Temporal development of the gut microbiome in early childhood from the TEDDY study. Nature 562:583–88
     [Google Scholar]
115. 115.

     Sun J, Furio L, Mecheri R, van der Does AM, Lundeberg E et al. 2015. Pancreatic β-cells limit autoimmune diabetes via an immunoregulatory antimicrobial peptide expressed under the influence of the gut microbiota. Immunity 43:304–17
     [Google Scholar]
116. 116.

     Surana NK, Kasper DL. 2017. Moving beyond microbiome-wide associations to causal microbe identification. Nature 552:244–47
     [Google Scholar]
117. 117.

     Tan C, Ling Z, Huang Y, Cao Y, Liu Q et al. 2015. Dysbiosis of intestinal microbiota associated with inflammation involved in the progression of acute pancreatitis. Pancreas 44:868–75
     [Google Scholar]
118. 118.

     Thomas RM, Gharaibeh RZ, Gauthier J, Beveridge M, Pope JL et al. 2018. Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models. Carcinogenesis 39:1068–78
     [Google Scholar]
119. 119.

     Tilg H, Adolph TE. 2017. Beyond digestion: the pancreas shapes intestinal microbiota and immunity. Cell Metab 25:495–96
     [Google Scholar]
120. 120.

     Tilg H, Adolph TE, Gerner RR, Moschen AR 2018. The intestinal microbiota in colorectal cancer. Cancer Cell 33:954–64
     [Google Scholar]
121. 121.

     Uhlig HH, Powrie F. 2018. Translating immunology into therapeutic concepts for inflammatory bowel disease. Annu. Rev. Immunol. 36:755–81
     [Google Scholar]
122. 122.

     Uusitalo U, Liu X, Yang J, Aronsson CA, Hummel S et al. 2016. Association of early exposure of probiotics and islet autoimmunity in the TEDDY study. JAMA Pediatr 170:20–28
     [Google Scholar]
123. 123.

     Vaarala O. 2002. The gut immune system and type 1 diabetes. Ann. N. Y. Acad. Sci. 958:39–46
     [Google Scholar]
124. 124.

     Vatanen T, Franzosa EA, Schwager R, Tripathi S, Arthur TD et al. 2018. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study. Nature 562:589–94
     [Google Scholar]
125. 125.

     Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW 2013. Cancer genome landscapes. Science 339:1546–58
     [Google Scholar]
126. 126.

     Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS et al. 2015. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495–501
     [Google Scholar]
127. 127.

     Watanabe T, Kudo M, Strober W 2017. Immunopathogenesis of pancreatitis. Mucosal Immunol 10:283–98
     [Google Scholar]
128. 128.

     Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L et al. 2008. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 455:1109–13
     [Google Scholar]
129. 129.

     Xiao AY, Tan ML, Wu LM, Asrani VM, Windsor JA et al. 2016. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. Lancet Gastroenterol. Hepatol. 1:45–55
     [Google Scholar]
130. 130.

     Yu H, Gagliani N, Ishigame H, Huber S, Zhu S et al. 2017. Intestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development. PNAS 114:10443–48
     [Google Scholar]
131. 131.

     Zambirinis CP, Levie E, Nguy S, Avanzi A, Barilla R et al. 2015. TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. J. Exp. Med. 212:2077–94
     [Google Scholar]